Subcutaneous Semaglutide as a Weight Loss Agent with Thomas Wadden, PhD


Check out the Endocrine Outlook podcast, brought to you by the Endocrinology Network. This episode focuses on semaglutide 1 mg as a weight loss therapy for patients who are obese or overweight.

Episode Highlights

1:52 - Key Takeaways from STEP 1 and STEP 3

4:00 - Procedures and Methods for Both Trials

9:55 - Adverse Event Profile

15:42 - Current Treatment Gaps in Obesity Management

18:25 - Is this Effect Specific to Semaglutide or all GLP1-RAs?

21:08 - If Approved, Who Should be Prescribing this Agent?

Editor's Note: This episode of the Endocrine Outlook podcast features Thomas Wadden, PhD, a professor of psychology at Perelman School of Medicine at the University of Penn. Wadden is also a principal investigator in the STEP Program, which is a series of clinical trials funded by Novo Nordisk examining subcutaneous semaglutide for inducing weight loss in patients who are obese or overweight.

During this episode, Wadden reviews the results of both STEP 1 and STEP 3, hypothesizes where this alternate dose of semaglutide could fit in treatment algorithms based on the available data, and who should ultimately be responsible for prescribing a weight loss therapy to patients. It should be mentioned his interview was recorded before the release of STEP 2 results and was therefore not included in discussion.

Check out our earlier coverage of STEP 1 and STEP 3.

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Daniel Gaudet, MD, PhD | Credit: American College of Cardiology
© 2024 MJH Life Sciences

All rights reserved.